Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Background malaria incidence and parasitemia during the three-dose RTS,S/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy against the first case of malaria

Fig. 1

Anti-CSP Antibody Response by Background Incidence, All Study Areas and Study Area Adjusted (A: Pre-Vaccination, B: One Month Post-Vaccination)

(A) Children have a very low anti-circumsporozoite protein (CSP) antibody response on the day of the first vaccine dose

(B) One month after vaccination, children in higher incidence areas have higher antibody responses to RTS,S/AS01 vaccination. This positive relationship disappears when adjusting for study area. Antibody responses were elevated in Ghana, the highest incidence study area

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us